Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stimulating Immune Response With Neoadjuvant Human Papilloma Virus (HPV)-16 Specific Vaccination in HPV-Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC)

NCT05232851 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05232851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05232851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stimulating Immune Response With Neoadjuvant Human Papilloma Virus (HPV)-16 Specific Vaccination in HPV-Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC)
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 16, 2022
Completion date
January 10, 2027
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, human papillomavirus-related carcinoma, locally advanced oropharyngeal carcinoma, stage iva oropharyngeal (p16-negative) carcinoma ajcc v8, stage ivb oropharyngeal (p16-negative) carcinoma ajcc v8